Global Kidney Fibrosis Drugs Market Growth 2023-2029

March 2023 | 90 pages | ID: GD33E21B8888EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Kidney Fibrosis Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Kidney Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Kidney Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Kidney Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Kidney Fibrosis Drugs players cover Merck and Co, Galectin Therapeutics, Pfizer Inc, InterMune Inc, La Jolla Pharmaceutical Company, BioLine Rx, F. Hoffman-La Roche, ProMetic Life-Sciences Inc and Genzyme Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Kidney Fibrosis Drugs Industry Forecast” looks at past sales and reviews total world Kidney Fibrosis Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Kidney Fibrosis Drugs sales for 2023 through 2029. With Kidney Fibrosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kidney Fibrosis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Kidney Fibrosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Kidney Fibrosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Kidney Fibrosis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney Fibrosis Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney Fibrosis Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Fibrosis Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

• Angiotensin Converting Enzyme (ACE) Inhibitors
• Pirfenidone
• Renin Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Vasopeptidase Inhibitors

Segmentation by application

• Chronic Kidney Diseases
• Kidney Cancer Treatment
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Merck and Co
• Galectin Therapeutics
• Pfizer Inc
• InterMune Inc
• La Jolla Pharmaceutical Company
• BioLine Rx
• F. Hoffman-La Roche
• ProMetic Life-Sciences Inc
• Genzyme Corporation

Key Questions Addressed in this Report

What is the 10-year outlook for the global Kidney Fibrosis Drugs market?

What factors are driving Kidney Fibrosis Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Kidney Fibrosis Drugs market opportunities vary by end market size?

How does Kidney Fibrosis Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Kidney Fibrosis Drugs Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for Kidney Fibrosis Drugs by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for Kidney Fibrosis Drugs by Country/Region, 2018, 2022 & 2029
2.2 Kidney Fibrosis Drugs Segment by Type
  2.2.1 Angiotensin Converting Enzyme (ACE) Inhibitors
  2.2.2 Pirfenidone
  2.2.3 Renin Inhibitors
  2.2.4 Angiotensin II Receptor Blockers (ARBs)
  2.2.5 Vasopeptidase Inhibitors
2.3 Kidney Fibrosis Drugs Sales by Type
  2.3.1 Global Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
  2.3.2 Global Kidney Fibrosis Drugs Revenue and Market Share by Type (2018-2023)
  2.3.3 Global Kidney Fibrosis Drugs Sale Price by Type (2018-2023)
2.4 Kidney Fibrosis Drugs Segment by Application
  2.4.1 Chronic Kidney Diseases
  2.4.2 Kidney Cancer Treatment
  2.4.3 Others
2.5 Kidney Fibrosis Drugs Sales by Application
  2.5.1 Global Kidney Fibrosis Drugs Sale Market Share by Application (2018-2023)
  2.5.2 Global Kidney Fibrosis Drugs Revenue and Market Share by Application (2018-2023)
  2.5.3 Global Kidney Fibrosis Drugs Sale Price by Application (2018-2023)

3 GLOBAL KIDNEY FIBROSIS DRUGS BY COMPANY

3.1 Global Kidney Fibrosis Drugs Breakdown Data by Company
  3.1.1 Global Kidney Fibrosis Drugs Annual Sales by Company (2018-2023)
  3.1.2 Global Kidney Fibrosis Drugs Sales Market Share by Company (2018-2023)
3.2 Global Kidney Fibrosis Drugs Annual Revenue by Company (2018-2023)
  3.2.1 Global Kidney Fibrosis Drugs Revenue by Company (2018-2023)
  3.2.2 Global Kidney Fibrosis Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Kidney Fibrosis Drugs Sale Price by Company
3.4 Key Manufacturers Kidney Fibrosis Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Kidney Fibrosis Drugs Product Location Distribution
  3.4.2 Players Kidney Fibrosis Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR KIDNEY FIBROSIS DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Kidney Fibrosis Drugs Market Size by Geographic Region (2018-2023)
  4.1.1 Global Kidney Fibrosis Drugs Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global Kidney Fibrosis Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Kidney Fibrosis Drugs Market Size by Country/Region (2018-2023)
  4.2.1 Global Kidney Fibrosis Drugs Annual Sales by Country/Region (2018-2023)
  4.2.2 Global Kidney Fibrosis Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Kidney Fibrosis Drugs Sales Growth
4.4 APAC Kidney Fibrosis Drugs Sales Growth
4.5 Europe Kidney Fibrosis Drugs Sales Growth
4.6 Middle East & Africa Kidney Fibrosis Drugs Sales Growth

5 AMERICAS

5.1 Americas Kidney Fibrosis Drugs Sales by Country
  5.1.1 Americas Kidney Fibrosis Drugs Sales by Country (2018-2023)
  5.1.2 Americas Kidney Fibrosis Drugs Revenue by Country (2018-2023)
5.2 Americas Kidney Fibrosis Drugs Sales by Type
5.3 Americas Kidney Fibrosis Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Kidney Fibrosis Drugs Sales by Region
  6.1.1 APAC Kidney Fibrosis Drugs Sales by Region (2018-2023)
  6.1.2 APAC Kidney Fibrosis Drugs Revenue by Region (2018-2023)
6.2 APAC Kidney Fibrosis Drugs Sales by Type
6.3 APAC Kidney Fibrosis Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Kidney Fibrosis Drugs by Country
  7.1.1 Europe Kidney Fibrosis Drugs Sales by Country (2018-2023)
  7.1.2 Europe Kidney Fibrosis Drugs Revenue by Country (2018-2023)
7.2 Europe Kidney Fibrosis Drugs Sales by Type
7.3 Europe Kidney Fibrosis Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Kidney Fibrosis Drugs by Country
  8.1.1 Middle East & Africa Kidney Fibrosis Drugs Sales by Country (2018-2023)
  8.1.2 Middle East & Africa Kidney Fibrosis Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Kidney Fibrosis Drugs Sales by Type
8.3 Middle East & Africa Kidney Fibrosis Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Kidney Fibrosis Drugs
10.3 Manufacturing Process Analysis of Kidney Fibrosis Drugs
10.4 Industry Chain Structure of Kidney Fibrosis Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Kidney Fibrosis Drugs Distributors
11.3 Kidney Fibrosis Drugs Customer

12 WORLD FORECAST REVIEW FOR KIDNEY FIBROSIS DRUGS BY GEOGRAPHIC REGION

12.1 Global Kidney Fibrosis Drugs Market Size Forecast by Region
  12.1.1 Global Kidney Fibrosis Drugs Forecast by Region (2024-2029)
  12.1.2 Global Kidney Fibrosis Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Kidney Fibrosis Drugs Forecast by Type
12.7 Global Kidney Fibrosis Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Merck and Co
  13.1.1 Merck and Co Company Information
  13.1.2 Merck and Co Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.1.3 Merck and Co Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 Merck and Co Main Business Overview
  13.1.5 Merck and Co Latest Developments
13.2 Galectin Therapeutics
  13.2.1 Galectin Therapeutics Company Information
  13.2.2 Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.2.3 Galectin Therapeutics Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 Galectin Therapeutics Main Business Overview
  13.2.5 Galectin Therapeutics Latest Developments
13.3 Pfizer Inc
  13.3.1 Pfizer Inc Company Information
  13.3.2 Pfizer Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.3.3 Pfizer Inc Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Pfizer Inc Main Business Overview
  13.3.5 Pfizer Inc Latest Developments
13.4 InterMune Inc
  13.4.1 InterMune Inc Company Information
  13.4.2 InterMune Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.4.3 InterMune Inc Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 InterMune Inc Main Business Overview
  13.4.5 InterMune Inc Latest Developments
13.5 La Jolla Pharmaceutical Company
  13.5.1 La Jolla Pharmaceutical Company Company Information
  13.5.2 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.5.3 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 La Jolla Pharmaceutical Company Main Business Overview
  13.5.5 La Jolla Pharmaceutical Company Latest Developments
13.6 BioLine Rx
  13.6.1 BioLine Rx Company Information
  13.6.2 BioLine Rx Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.6.3 BioLine Rx Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 BioLine Rx Main Business Overview
  13.6.5 BioLine Rx Latest Developments
13.7 F. Hoffman-La Roche
  13.7.1 F. Hoffman-La Roche Company Information
  13.7.2 F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.7.3 F. Hoffman-La Roche Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.7.4 F. Hoffman-La Roche Main Business Overview
  13.7.5 F. Hoffman-La Roche Latest Developments
13.8 ProMetic Life-Sciences Inc
  13.8.1 ProMetic Life-Sciences Inc Company Information
  13.8.2 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.8.3 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.8.4 ProMetic Life-Sciences Inc Main Business Overview
  13.8.5 ProMetic Life-Sciences Inc Latest Developments
13.9 Genzyme Corporation
  13.9.1 Genzyme Corporation Company Information
  13.9.2 Genzyme Corporation Kidney Fibrosis Drugs Product Portfolios and Specifications
  13.9.3 Genzyme Corporation Kidney Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.9.4 Genzyme Corporation Main Business Overview
  13.9.5 Genzyme Corporation Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Kidney Fibrosis Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Kidney Fibrosis Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Angiotensin Converting Enzyme (ACE) Inhibitors
Table 4. Major Players of Pirfenidone
Table 5. Major Players of Renin Inhibitors
Table 6. Major Players of Angiotensin II Receptor Blockers (ARBs)
Table 7. Major Players of Vasopeptidase Inhibitors
Table 8. Global Kidney Fibrosis Drugs Sales by Type (2018-2023) & (K Units)
Table 9. Global Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
Table 10. Global Kidney Fibrosis Drugs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Kidney Fibrosis Drugs Revenue Market Share by Type (2018-2023)
Table 12. Global Kidney Fibrosis Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Kidney Fibrosis Drugs Sales by Application (2018-2023) & (K Units)
Table 14. Global Kidney Fibrosis Drugs Sales Market Share by Application (2018-2023)
Table 15. Global Kidney Fibrosis Drugs Revenue by Application (2018-2023)
Table 16. Global Kidney Fibrosis Drugs Revenue Market Share by Application (2018-2023)
Table 17. Global Kidney Fibrosis Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Kidney Fibrosis Drugs Sales by Company (2018-2023) & (K Units)
Table 19. Global Kidney Fibrosis Drugs Sales Market Share by Company (2018-2023)
Table 20. Global Kidney Fibrosis Drugs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Kidney Fibrosis Drugs Revenue Market Share by Company (2018-2023)
Table 22. Global Kidney Fibrosis Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Kidney Fibrosis Drugs Producing Area Distribution and Sales Area
Table 24. Players Kidney Fibrosis Drugs Products Offered
Table 25. Kidney Fibrosis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Kidney Fibrosis Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Kidney Fibrosis Drugs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Kidney Fibrosis Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Kidney Fibrosis Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Kidney Fibrosis Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Kidney Fibrosis Drugs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Kidney Fibrosis Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Kidney Fibrosis Drugs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Kidney Fibrosis Drugs Sales by Country (2018-2023) & (K Units)
Table 37. Americas Kidney Fibrosis Drugs Sales Market Share by Country (2018-2023)
Table 38. Americas Kidney Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Kidney Fibrosis Drugs Revenue Market Share by Country (2018-2023)
Table 40. Americas Kidney Fibrosis Drugs Sales by Type (2018-2023) & (K Units)
Table 41. Americas Kidney Fibrosis Drugs Sales by Application (2018-2023) & (K Units)
Table 42. APAC Kidney Fibrosis Drugs Sales by Region (2018-2023) & (K Units)
Table 43. APAC Kidney Fibrosis Drugs Sales Market Share by Region (2018-2023)
Table 44. APAC Kidney Fibrosis Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Kidney Fibrosis Drugs Revenue Market Share by Region (2018-2023)
Table 46. APAC Kidney Fibrosis Drugs Sales by Type (2018-2023) & (K Units)
Table 47. APAC Kidney Fibrosis Drugs Sales by Application (2018-2023) & (K Units)
Table 48. Europe Kidney Fibrosis Drugs Sales by Country (2018-2023) & (K Units)
Table 49. Europe Kidney Fibrosis Drugs Sales Market Share by Country (2018-2023)
Table 50. Europe Kidney Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Kidney Fibrosis Drugs Revenue Market Share by Country (2018-2023)
Table 52. Europe Kidney Fibrosis Drugs Sales by Type (2018-2023) & (K Units)
Table 53. Europe Kidney Fibrosis Drugs Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Kidney Fibrosis Drugs Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Kidney Fibrosis Drugs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Kidney Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Kidney Fibrosis Drugs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Kidney Fibrosis Drugs Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Kidney Fibrosis Drugs Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Kidney Fibrosis Drugs
Table 61. Key Market Challenges & Risks of Kidney Fibrosis Drugs
Table 62. Key Industry Trends of Kidney Fibrosis Drugs
Table 63. Kidney Fibrosis Drugs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Kidney Fibrosis Drugs Distributors List
Table 66. Kidney Fibrosis Drugs Customer List
Table 67. Global Kidney Fibrosis Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Kidney Fibrosis Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Kidney Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Kidney Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Kidney Fibrosis Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Kidney Fibrosis Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Kidney Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Kidney Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Kidney Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Kidney Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Kidney Fibrosis Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Kidney Fibrosis Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Kidney Fibrosis Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Kidney Fibrosis Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Merck and Co Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Merck and Co Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 83. Merck and Co Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Merck and Co Main Business
Table 85. Merck and Co Latest Developments
Table 86. Galectin Therapeutics Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Galectin Therapeutics Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 88. Galectin Therapeutics Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Galectin Therapeutics Main Business
Table 90. Galectin Therapeutics Latest Developments
Table 91. Pfizer Inc Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Pfizer Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 93. Pfizer Inc Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Pfizer Inc Main Business
Table 95. Pfizer Inc Latest Developments
Table 96. InterMune Inc Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. InterMune Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 98. InterMune Inc Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. InterMune Inc Main Business
Table 100. InterMune Inc Latest Developments
Table 101. La Jolla Pharmaceutical Company Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 103. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. La Jolla Pharmaceutical Company Main Business
Table 105. La Jolla Pharmaceutical Company Latest Developments
Table 106. BioLine Rx Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. BioLine Rx Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 108. BioLine Rx Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. BioLine Rx Main Business
Table 110. BioLine Rx Latest Developments
Table 111. F. Hoffman-La Roche Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. F. Hoffman-La Roche Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 113. F. Hoffman-La Roche Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. F. Hoffman-La Roche Main Business
Table 115. F. Hoffman-La Roche Latest Developments
Table 116. ProMetic Life-Sciences Inc Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 118. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. ProMetic Life-Sciences Inc Main Business
Table 120. ProMetic Life-Sciences Inc Latest Developments
Table 121. Genzyme Corporation Basic Information, Kidney Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Genzyme Corporation Kidney Fibrosis Drugs Product Portfolios and Specifications
Table 123. Genzyme Corporation Kidney Fibrosis Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Genzyme Corporation Main Business
Table 125. Genzyme Corporation Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Kidney Fibrosis Drugs
Figure 2. Kidney Fibrosis Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Kidney Fibrosis Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Kidney Fibrosis Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Kidney Fibrosis Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Angiotensin Converting Enzyme (ACE) Inhibitors
Figure 10. Product Picture of Pirfenidone
Figure 11. Product Picture of Renin Inhibitors
Figure 12. Product Picture of Angiotensin II Receptor Blockers (ARBs)
Figure 13. Product Picture of Vasopeptidase Inhibitors
Figure 14. Global Kidney Fibrosis Drugs Sales Market Share by Type in 2022
Figure 15. Global Kidney Fibrosis Drugs Revenue Market Share by Type (2018-2023)
Figure 16. Kidney Fibrosis Drugs Consumed in Chronic Kidney Diseases
Figure 17. Global Kidney Fibrosis Drugs Market: Chronic Kidney Diseases (2018-2023) & (K Units)
Figure 18. Kidney Fibrosis Drugs Consumed in Kidney Cancer Treatment
Figure 19. Global Kidney Fibrosis Drugs Market: Kidney Cancer Treatment (2018-2023) & (K Units)
Figure 20. Kidney Fibrosis Drugs Consumed in Others
Figure 21. Global Kidney Fibrosis Drugs Market: Others (2018-2023) & (K Units)
Figure 22. Global Kidney Fibrosis Drugs Sales Market Share by Application (2022)
Figure 23. Global Kidney Fibrosis Drugs Revenue Market Share by Application in 2022
Figure 24. Kidney Fibrosis Drugs Sales Market by Company in 2022 (K Units)
Figure 25. Global Kidney Fibrosis Drugs Sales Market Share by Company in 2022
Figure 26. Kidney Fibrosis Drugs Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Kidney Fibrosis Drugs Revenue Market Share by Company in 2022
Figure 28. Global Kidney Fibrosis Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Kidney Fibrosis Drugs Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Kidney Fibrosis Drugs Sales 2018-2023 (K Units)
Figure 31. Americas Kidney Fibrosis Drugs Revenue 2018-2023 ($ Millions)
Figure 32. APAC Kidney Fibrosis Drugs Sales 2018-2023 (K Units)
Figure 33. APAC Kidney Fibrosis Drugs Revenue 2018-2023 ($ Millions)
Figure 34. Europe Kidney Fibrosis Drugs Sales 2018-2023 (K Units)
Figure 35. Europe Kidney Fibrosis Drugs Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Kidney Fibrosis Drugs Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Kidney Fibrosis Drugs Revenue 2018-2023 ($ Millions)
Figure 38. Americas Kidney Fibrosis Drugs Sales Market Share by Country in 2022
Figure 39. Americas Kidney Fibrosis Drugs Revenue Market Share by Country in 2022
Figure 40. Americas Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
Figure 41. Americas Kidney Fibrosis Drugs Sales Market Share by Application (2018-2023)
Figure 42. United States Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Kidney Fibrosis Drugs Sales Market Share by Region in 2022
Figure 47. APAC Kidney Fibrosis Drugs Revenue Market Share by Regions in 2022
Figure 48. APAC Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
Figure 49. APAC Kidney Fibrosis Drugs Sales Market Share by Application (2018-2023)
Figure 50. China Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Kidney Fibrosis Drugs Sales Market Share by Country in 2022
Figure 58. Europe Kidney Fibrosis Drugs Revenue Market Share by Country in 2022
Figure 59. Europe Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
Figure 60. Europe Kidney Fibrosis Drugs Sales Market Share by Application (2018-2023)
Figure 61. Germany Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Kidney Fibrosis Drugs Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Kidney Fibrosis Drugs Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Kidney Fibrosis Drugs Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Kidney Fibrosis Drugs Sales Market Share by Application (2018-2023)
Figure 70. Egypt Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Kidney Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Kidney Fibrosis Drugs in 2022
Figure 76. Manufacturing Process Analysis of Kidney Fibrosis Drugs
Figure 77. Industry Chain Structure of Kidney Fibrosis Drugs
Figure 78. Channels of Distribution
Figure 79. Global Kidney Fibrosis Drugs Sales Market Forecast by Region (2024-2029)
Figure 80. Global Kidney Fibrosis Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Kidney Fibrosis Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Kidney Fibrosis Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Kidney Fibrosis Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Kidney Fibrosis Drugs Revenue Market Share Forecast by Application (2024-2029)